Calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide in migraine treatment
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Purpose of reviewTo review the latest advances in migraine management with a focus on medications specifically developed for the treatment of migraine.Recent findingsRandomized clinical trials demonstrated the efficacy of calcitonin gene-related peptide (CGRP) mAbs for the preventive treatment of migraine and the small molecule CGRP receptor antagonist gepants for acute abortion and prevention of migraine attacks. Pituitary adenylate cyclase-activating polypeptide (PACAP) is another signaling molecule of interest and represents a potential new drug class of mechanism-based migraine medications. Drugs targeting PACAP are currently undergoing clinical trials, and the coming years will reveal whether this class of drugs will expand our therapeutic armamentarium.SummaryHere, we summarize the role of CGRP and PACAP in migraine pathophysiology and discuss novel therapies targeting the CGRP and PACAP signaling pathways.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Current Opinion in Endocrinology, Diabetes and Obesity |
Vol/bind | 29 |
Udgave nummer | 2 |
Sider (fra-til) | 225-231 |
Antal sider | 7 |
ISSN | 1752-296X |
DOI | |
Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:
M.A. was supported by the Lundbeck Foundation professor grant (R310-2018-3711).
Funding Information:
M.A. has received personal fees from AbbVie/Allergan, Amgen, Eli Lilly, Lundbeck, Novartis, and Teva Pharmaceuticals. He is the principal investigator for ongoing clinical trials for AbbVie, Amgen, and Lundbeck. He has received research grants from Lundbeck Foundation, Novo Nordisk Foundation, and Novartis. He serves as associate editor of Brain, Cephalalgia, and The Journal of Headache and Pain. R.D.-M. and T.P.D. report no conflicts of interest.
Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.
ID: 344980847